https://media-us.eisai.com/ Eisai Newsroom https://media-us.eisai.com/2026-08-24-LEQEMBI-IQLIK-R-lecanemab-irmb-Autoinjector-for-Initiation-of-Therapy-Now-Available-in-the-U-S-for-Early-Alzheimers-Disease Mon, 24 Aug 2026 08:00:00 -0400 https://media-us.eisai.com/2026-08-24-LEQEMBI-IQLIK-R-lecanemab-irmb-Autoinjector-for-Initiation-of-Therapy-Now-Available-in-the-U-S-for-Early-Alzheimers-Disease https://media-us.eisai.com/2026-07-14-LEQEMBI-R-Real-World-LEADER-Study-Presented-at-AAIC-R-2026-Finds-Over-75-of-Early-Alzheimers-Patients-Enrolled-in-the-Study-Remained-Stable-and-Nearly-7-Improved-Over-an-Average-of-17-Months-of-Treatment Tue, 14 Jul 2026 11:15:00 -0400 https://media-us.eisai.com/2026-07-14-LEQEMBI-R-Real-World-LEADER-Study-Presented-at-AAIC-R-2026-Finds-Over-75-of-Early-Alzheimers-Patients-Enrolled-in-the-Study-Remained-Stable-and-Nearly-7-Improved-Over-an-Average-of-17-Months-of-Treatment https://media-us.eisai.com/2026-07-13-FDA-Approves-LEQEMBI-IQLIK-R-lecanemab-irmb-Subcutaneous-Injection-as-an-Initiation-Dose-for-Early-Alzheimers-Disease Mon, 13 Jul 2026 17:36:00 -0400 https://media-us.eisai.com/2026-07-13-FDA-Approves-LEQEMBI-IQLIK-R-lecanemab-irmb-Subcutaneous-Injection-as-an-Initiation-Dose-for-Early-Alzheimers-Disease https://media-us.eisai.com/2026-07-13-Eisai-Presents-Latest-Findings-Showed-Etalanetug-Reduced-Alzheimers-Disease-Tau-Tangle-Specific-Plasma-Biomarker-MTBR-tau243-at-Alzheimers-Association-International-Conference-R-AAIC-R-2026 Mon, 13 Jul 2026 04:00:00 -0400 https://media-us.eisai.com/2026-07-13-Eisai-Presents-Latest-Findings-Showed-Etalanetug-Reduced-Alzheimers-Disease-Tau-Tangle-Specific-Plasma-Biomarker-MTBR-tau243-at-Alzheimers-Association-International-Conference-R-AAIC-R-2026 https://media-us.eisai.com/2026-07-12-LEQEMBI-R-Subcutaneous-Autoinjector-Clinical-Data-Supports-Similar-Efficacy-and-Safety-to-IV-Formulation-in-Early-Alzheimers-Disease-Presented-at-the-Alzheimers-Association-International-Conference-R-AAIC-R-2026 Sun, 12 Jul 2026 11:15:00 -0400 https://media-us.eisai.com/2026-07-12-LEQEMBI-R-Subcutaneous-Autoinjector-Clinical-Data-Supports-Similar-Efficacy-and-Safety-to-IV-Formulation-in-Early-Alzheimers-Disease-Presented-at-the-Alzheimers-Association-International-Conference-R-AAIC-R-2026 https://media-us.eisai.com/2026-06-29-Eisai-to-Showcase-Alzheimers-Disease-Portfolio-with-More-Than-50-Presentations-at-the-Alzheimers-Association-International-Conference-R-2026-AAIC-R Mon, 29 Jun 2026 07:30:00 -0400 https://media-us.eisai.com/2026-06-29-Eisai-to-Showcase-Alzheimers-Disease-Portfolio-with-More-Than-50-Presentations-at-the-Alzheimers-Association-International-Conference-R-2026-AAIC-R https://media-us.eisai.com/2026-06-01-Eisai-and-CaringKind-Launch-New-Initiative-to-Address-Mealtime-and-Nutrition-Needs-for-People-Living-with-Alzheimers-Disease-and-Related-Dementias Mon, 01 Jun 2026 07:00:00 -0400 https://media-us.eisai.com/2026-06-01-Eisai-and-CaringKind-Launch-New-Initiative-to-Address-Mealtime-and-Nutrition-Needs-for-People-Living-with-Alzheimers-Disease-and-Related-Dementias https://media-us.eisai.com/2026-05-20-Eisai-Deepens-Body-of-Clinical-Evidence-for-LENVIMA-Lenvatinib-Across-Established-Indications-at-ASCO-2026 Wed, 20 May 2026 08:08:00 -0400 https://media-us.eisai.com/2026-05-20-Eisai-Deepens-Body-of-Clinical-Evidence-for-LENVIMA-Lenvatinib-Across-Established-Indications-at-ASCO-2026 https://media-us.eisai.com/2026-05-08-Update-on-FDA-Priority-Review-of-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-as-a-Starting-Dose-for-Early-Alzheimers-Disease Fri, 08 May 2026 02:30:00 -0400 https://media-us.eisai.com/2026-05-08-Update-on-FDA-Priority-Review-of-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-as-a-Starting-Dose-for-Early-Alzheimers-Disease https://media-us.eisai.com/2026-04-10-New-Survey-Data-Exploring-Patient-Experiences-with-Endometrial-Cancer-Care-Presented-at-2026-Society-of-Gynecologic-Oncology-SGO-Annual-Meeting-on-Womens-Cancer Fri, 10 Apr 2026 07:00:00 -0400 https://media-us.eisai.com/2026-04-10-New-Survey-Data-Exploring-Patient-Experiences-with-Endometrial-Cancer-Care-Presented-at-2026-Society-of-Gynecologic-Oncology-SGO-Annual-Meeting-on-Womens-Cancer https://media-us.eisai.com/2026-04-09-Eisai-to-Present-the-Latest-Data-on-Real-World-Treatment-with-Lecanemab-and-Supporting-a-Standardized-Framework-for-Treating-Early-Alzheimers-Disease-at-the-78th-American-Academy-of-Neurologys-Annual-Meeting Thu, 09 Apr 2026 08:00:00 -0400 https://media-us.eisai.com/2026-04-09-Eisai-to-Present-the-Latest-Data-on-Real-World-Treatment-with-Lecanemab-and-Supporting-a-Standardized-Framework-for-Treating-Early-Alzheimers-Disease-at-the-78th-American-Academy-of-Neurologys-Annual-Meeting https://media-us.eisai.com/2026-03-26-EISAI-TO-BEGIN-ENROLLING-PHASE-2-STUDY-IN-PATIENTS-WITH-NARCOLEPSY Thu, 26 Mar 2026 08:00:00 -0400 https://media-us.eisai.com/2026-03-26-EISAI-TO-BEGIN-ENROLLING-PHASE-2-STUDY-IN-PATIENTS-WITH-NARCOLEPSY https://media-us.eisai.com/2026-03-20-Results-from-Real-World,-Long-Term-Treatment-Persistence-with-LEQEMBI-R-lecanemab-irmb-in-the-United-States-Presented-at-AD-PD-TM-2026 Fri, 20 Mar 2026 12:05:00 -0400 https://media-us.eisai.com/2026-03-20-Results-from-Real-World,-Long-Term-Treatment-Persistence-with-LEQEMBI-R-lecanemab-irmb-in-the-United-States-Presented-at-AD-PD-TM-2026 https://media-us.eisai.com/2026-03-10-Eisai-to-Present-the-Latest-Data-on-Long-Term,-Real-World-Treatment-with-Lecanemab-at-the-AD-PD-TM-2026-Annual-Meeting Tue, 10 Mar 2026 19:30:00 -0400 https://media-us.eisai.com/2026-03-10-Eisai-to-Present-the-Latest-Data-on-Long-Term,-Real-World-Treatment-with-Lecanemab-at-the-AD-PD-TM-2026-Annual-Meeting https://media-us.eisai.com/2026-02-26-Eisai-and-Advocacy-Leaders-Launch-Kompass,-a-Digital-Destination-to-Help-Patients-and-Caregivers-Navigate-the-Complexities-of-Kidney-Cancer Thu, 26 Feb 2026 08:08:00 -0500 https://media-us.eisai.com/2026-02-26-Eisai-and-Advocacy-Leaders-Launch-Kompass,-a-Digital-Destination-to-Help-Patients-and-Caregivers-Navigate-the-Complexities-of-Kidney-Cancer https://media-us.eisai.com/2026-01-25-FDA-Accepts-LEQEMBI-R-IQLIKTM-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-under-Priority-Review Sun, 25 Jan 2026 18:30:00 -0500 https://media-us.eisai.com/2026-01-25-FDA-Accepts-LEQEMBI-R-IQLIKTM-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-under-Priority-Review https://media-us.eisai.com/2025-12-03-Eisai-Presents-New-Data-on-the-Continued-and-Expanding-Benefit-of-LEQEMBI-R-lecanemab-irmb-Maintenance-Treatment-in-Early-Alzheimers-Disease-at-the-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference-2025 Wed, 03 Dec 2025 18:10:00 -0500 https://media-us.eisai.com/2025-12-03-Eisai-Presents-New-Data-on-the-Continued-and-Expanding-Benefit-of-LEQEMBI-R-lecanemab-irmb-Maintenance-Treatment-in-Early-Alzheimers-Disease-at-the-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference-2025 https://media-us.eisai.com/2025-12-02-New-Data-Presented-at-the-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference-2025-Confirms-Pharmacological-Effect-of-LEQEMBI-R-lecanemab-irmb-on-Neurotoxic-A-Protofibrils-in-CSF Tue, 02 Dec 2025 16:40:00 -0500 https://media-us.eisai.com/2025-12-02-New-Data-Presented-at-the-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference-2025-Confirms-Pharmacological-Effect-of-LEQEMBI-R-lecanemab-irmb-on-Neurotoxic-A-Protofibrils-in-CSF https://media-us.eisai.com/2025-12-01-Eisai-Presents-New-Data-on-Anti-Tau-Antibody-Etalanetug-E2814-at-CTAD-2025 Mon, 01 Dec 2025 19:35:00 -0500 https://media-us.eisai.com/2025-12-01-Eisai-Presents-New-Data-on-Anti-Tau-Antibody-Etalanetug-E2814-at-CTAD-2025 https://media-us.eisai.com/2025-11-25-Eisai-Completes-Rolling-Submission-to-U-S-FDA-for-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-Under-Fast-Track-Status Tue, 25 Nov 2025 07:30:00 -0500 https://media-us.eisai.com/2025-11-25-Eisai-Completes-Rolling-Submission-to-U-S-FDA-for-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Supplemental-Biologics-License-Application-as-a-Subcutaneous-Starting-Dose-for-the-Treatment-of-Early-Alzheimers-Disease-Under-Fast-Track-Status https://media-us.eisai.com/2025-11-18-Eisai-to-Present-Data-on-Lecanemab-Continued-Treatment,-Subcutaneous-Initiation-Dosing,-and-Real-World-Experience-at-the-18th-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference Tue, 18 Nov 2025 08:00:00 -0500 https://media-us.eisai.com/2025-11-18-Eisai-to-Present-Data-on-Lecanemab-Continued-Treatment,-Subcutaneous-Initiation-Dosing,-and-Real-World-Experience-at-the-18th-Clinical-Trials-on-Alzheimers-Disease-CTAD-Conference https://media-us.eisai.com/2025-11-03-Eisai-Demonstrates-Commitment-to-Advanced-Endometrial-Cancer-Care-at-IGCS-2025 Mon, 03 Nov 2025 08:08:00 -0500 https://media-us.eisai.com/2025-11-03-Eisai-Demonstrates-Commitment-to-Advanced-Endometrial-Cancer-Care-at-IGCS-2025 https://media-us.eisai.com/2025-10-13-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Autoinjector-Named-to-TIMEs-Best-Inventions-of-2025 Mon, 13 Oct 2025 19:30:00 -0400 https://media-us.eisai.com/2025-10-13-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Autoinjector-Named-to-TIMEs-Best-Inventions-of-2025 https://media-us.eisai.com/2025-10-06-Eisai-and-Biogen-Announce-U-S-Availability-of-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease Mon, 06 Oct 2025 16:30:00 -0400 https://media-us.eisai.com/2025-10-06-Eisai-and-Biogen-Announce-U-S-Availability-of-LEQEMBI-R-IQLIK-TM-lecanemab-irmb-Subcutaneous-Injection-Maintenance-Dose-for-Treatment-of-Early-Alzheimers-Disease https://media-us.eisai.com/2025-10-02-Eisai-Highlights-Breadth-of-Oncology-Research-at-ESMO-2025,-Featuring-5-Year-Survival-Data-from-Study-309-KEYNOTE-775 Thu, 02 Oct 2025 08:08:00 -0400 https://media-us.eisai.com/2025-10-02-Eisai-Highlights-Breadth-of-Oncology-Research-at-ESMO-2025,-Featuring-5-Year-Survival-Data-from-Study-309-KEYNOTE-775